|Day Low/High||21.15 / 22.00|
|52 Wk Low/High||6.17 / 19.76|
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Versartis Inc , where a total volume of 1,652 contracts has been traded thus far today, a contract volume which is representative of approximately 165,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 56.8% of VSAR's average daily trading volume over the past month, of 291,100 shares.
Confirms Phase 3 Data Expected Late September
Investors eyeing a purchase of Versartis Inc shares, but tentative about paying the going market price of $16.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $12.50 strike, which has a bid at the time of this writing of $2.90.
Levi & Korsinsky, LLP announces it has commenced an investigation of Versartis Inc.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
- Mean height velocity during Years 1, 2, and 3 remained consistent and in line with U.S. daily rhGH treatment
- Baseline characteristics of Phase 3 VELOCITY trial population balanced between study arms and comparable to Phase 2
Insiders at these companies have been scooping up shares in their own organizations lately.
Insiders at Infinity Pharmaceuticals and Och-Ziff Capital Management Group -- among other companies -- have been scooping up shares of their own stock lately.
Investors eyeing a purchase of Versartis Inc stock, but cautious about paying the going market price of $12.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2017 put at the $10 strike, which has a bid at the time of this writing of $1.35.
Increasing somavaratan dose to the 3.5mg/kg twice-monthly now used in Phase 3 safely improved IGF-I SDS and height velocity from year 1 to year 2
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.